KIRIT V. GALA, MD

Plain English
This study looked at how well a new type of MRI, called FRACTURE MRI, performs compared to traditional X-rays and CT scans when diagnosing bone tumors. It involved 161 patients and found that FRACTURE MRI had very high agreement with X-rays and CT in identifying the type of tumor, its location, and how well treatment was working. For example, the agreement on tumor type was nearly perfect, with scores ranging from 0.90 to 1.00, indicating that FRACTURE MRI can be trusted for these evaluations. Who this helps: This benefits patients with bone tumors and their doctors by providing accurate imaging options.

Plain English
This study looked at two methods of draining the gallbladder using endoscopic ultrasound: transgastric (TG) and transduodenal (TD) paths, involving 82 patients mostly around 72 years old. Both methods were similarly effective, with clinical success rates of 89% for TD and 94% for TG, and no major differences in complications or the need for further procedures. The research suggests both methods are safe, allowing doctors to choose based on what works best for each patient. Who this helps: This helps patients with gallbladder issues and their doctors by providing effective treatment options.

Plain English
This study looked at a patient with advanced stomach cancer who developed a blockage in the bile ducts after surgery. Researchers used a combined approach that involved two procedures to place metal stents for draining bile more effectively, which helped avoid the need for frequent stent changes. After 8 months, the patient was healthy, with stable liver function and properly positioned stents, showing that this method can be a good alternative for similar cases. Who this helps: This helps patients with complex bile duct obstructions resulting from cancer or previous surgeries.

Plain English
This study looked at how a peer mentoring program called Coach Mpilo helps South African men affected by tuberculosis (TB) and HIV improve their health by addressing traditional ideas of masculinity. Researchers interviewed 20 male coaches, all of whom have survived TB or live with HIV, and found that societal expectations often prevent men from seeking care and adhering to treatment. By encouraging these men to view seeking help as a sign of strength, and by creating supportive environments, the program has the potential to improve health outcomes and reduce the impact of TB and HIV among men. Who this helps: This benefits men with TB and HIV, as well as healthcare providers working with them.

Plain English
This study looked at 30 patients with rare tumors called retroperitoneal paragangliomas (RP-PGLs) that can cause serious health issues if not treated. The researchers found that after surgery, 95.5% of patients were alive three years later, and 89.1% were free of disease, indicating that surgery is effective. This matters because it shows that proper surgical management can lead to strong long-term health outcomes for patients suffering from these tumors. Who this helps: Patients with retroperitoneal paragangliomas and their doctors.

Plain English
This study focused on how to best treat a type of liver cancer called unresectable hepatocellular carcinoma (HCC) in India, where many cases are diagnosed at advanced stages. A panel of 22 healthcare experts created 40 agreement statements based on their expertise and current literature, covering topics like the definition of unresectable HCC and possible treatment options. This research is significant because it provides step-by-step guidance for doctors in India to improve patient care, especially when surgical options aren’t available. Who this helps: This helps patients with advanced liver cancer and their doctors.

Plain English
This study looked at the experiences and long-term health outcomes of young people with bone cancer (specifically osteosarcoma and Ewing sarcoma) in India over a ten-year period. Among 481 patients with nonmetastatic osteosarcoma, about 59% were still alive and free from disease after five years, while only about 19% of those with metastatic osteosarcoma achieved similar results. The research highlights the need for better support in treatment compliance and fertility preservation, as many young patients faced significant life interruptions during their treatment. Who this helps: This research benefits patients with bone sarcomas and their healthcare providers.

Plain English
This study looked at how well patients prepared their bowels for colonoscopy, comparing those who were taking a specific type of medication called glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to those who weren't. They found that patients on GLP-1 RAs had worse bowel preparation, with significantly lower scores on the preparation scale—meaning they didn't prepare as well for the procedure. This matters because poor bowel preparation can make colonoscopies less effective and increase the chances of missing issues like cancer. Who this helps: This helps patients undergoing colonoscopy and their healthcare providers.

Plain English
This study looked at how effective a treatment called transarterial chemoembolization (TACE) is before surgery for patients with intermediate-stage liver cancer (known as HKLC stage IIB). Researchers found that patients who had TACE before their surgery lived longer, with a median survival of about 90.97 months, compared to 30.68 months for those who went straight to surgery. This difference is important because it shows that TACE can help doctors better choose patients who will benefit from surgery, leading to significantly improved survival rates. Who this helps: This benefits patients with intermediate-stage liver cancer and their doctors.

Plain English
This study looked at the outcomes of adolescents and young adults with bone cancers called osteosarcoma and Ewing sarcoma. Researchers analyzed data from over 700 patients treated at a cancer center in India and created a risk-scoring system that identified key factors affecting survival rates, such as not completing treatment and the presence of metastasis. For example, patients with Ewing sarcoma who did not complete their treatment had a risk of complications over six times higher than those who did. Who this helps: This helps patients by identifying their risk levels and guiding treatment decisions for better outcomes.

Plain English
This research explores a dental technique called immediate dentin sealing (IDS) that helps strengthen the bond between teeth and restorative materials. The review shows that using IDS can improve bonding strength, decrease post-procedure sensitivity, and enhance the lifespan of dental restorations. This is important because it leads to better outcomes for dental patients, making their restorations last longer and feel more comfortable. Who this helps: Patients receiving dental restorations.

Plain English
This study looked at how using liners during the treatment of deep tooth decay affects the health of the tooth's inner pulp after a year. Researchers found that using a liner made no significant difference in maintaining pulp vitality, with both treated and untreated groups showing similar results (with statistical data showing no major difference). This matters because it questions the need for liners in certain dental treatments, potentially simplifying procedures and reducing costs. Who this helps: This helps both dentists and patients by informing treatment choices.

Plain English
This study looked at why people still experience gastroesophageal reflux disease (GERD) symptoms after undergoing Roux-en-Y gastric bypass surgery, which is normally expected to reduce reflux. Researchers found that all 42 patients examined had hiatal hernias of various sizes, with an average size of 2.07 cm, and that 90% had a severe condition at the esophagogastric junction. The use of proton pump inhibitors (PPIs) to manage reflux symptoms actually increased after surgery, going from 42.9% to 69% of patients. Who this helps: This benefits patients who have undergone gastric bypass and continue to suffer from reflux symptoms.

Plain English
This study examines how the treatment of childhood cancers in India is evolving, highlighting that 80% of children who receive modern therapies are expected to survive into adulthood. However, while these contemporary treatments improve survival rates, they can also lead to significant side effects that affect quality of life, especially when dealing with advanced or rare cancers. The researchers emphasize the need for better access to advanced treatments and support systems in low-income countries, as many of the latest options are not available there. Who this helps: This benefits children with cancer and their families, as well as healthcare providers in low- and middle-income countries.

Plain English
This study focused on understanding the genetic changes in hormone therapy-resistant breast cancer that is hormone receptor-positive and HER2-negative. Researchers compared 48 patients whose cancer progressed within two years of treatment to 19 patients who remained cancer-free for over two years. They discovered that the cancer in resistant patients had more mutations, with 78.9% showing actionable mutations that could inform treatment decisions, and they found 27 significant mutations in 71.4% of resistant patients through blood tests. Who this helps: Patients with hormone therapy-resistant breast cancer and their doctors.

Plain English
This study focused on a rare group of liver tumors in children that are not hepatoblastomas. Researchers looked at 69 cases from 2012 to 2023 and found that infantile hepatic hemangiomas were the most common at 66.7%, while hepatocellular carcinoma was prevalent in older children, making up 45.4% of cases in those over 10 years old. Most patients received treatment, with surgery being the most common approach at 85.2%, and the overall outcomes for treated tumors were considered relatively favorable. Who this helps: This research helps doctors by providing insights into the types of liver tumors in children and their treatment outcomes.

Plain English
This study looked at whether patients who pay for an obesity treatment called endoscopic sleeve gastroplasty (ESG) out of their own pockets do better than those who get the treatment covered by clinical trials. The researchers found that, after six months to two years, both groups lost about the same amount of weight—14% for those paying out of pocket and 12.9% for those with no costs—and had similar levels of treatment adherence. This is important because it shows that financial investment doesn't lead to better results, highlighting the need for insurance coverage to make this helpful procedure more accessible. Who this helps: This benefits patients struggling with obesity who need affordable treatment options.

Plain English
This study looked at how well different groups of people are represented in clinical trials for gastrointestinal diseases like inflammatory bowel disease and irritable bowel syndrome from 2000 to 2023. It found that older adults, women in some trials, and racial minorities were not adequately included; for example, most participants were aged 18 to 65, and Black, Asian, and Hispanic individuals were particularly underrepresented. This matters because more diverse trial groups can lead to better treatment outcomes for everyone by ensuring that findings apply to all populations. Who this helps: This helps patients and doctors by promoting more effective treatments tailored to a diverse range of individuals.

Plain English
This study looked at a rare but serious condition called esophago-pleural fistula (EPF), which can happen after certain surgeries, making it hard for patients to eat or breathe. Researchers treated a 34-year-old man who couldn't have surgery using a combination of a stent and an endobronchial valve, which led to the closure of the fistula after six months. This technique is important because it offers a less invasive treatment option for patients who cannot undergo surgery. Who this helps: This benefits patients with EPF who are not candidates for surgery.

Plain English
The study examined how new electronic health record (EHR) tools helped improve the diagnosis and treatment of hepatitis C (HCV) in New York City’s health system. After these tools were introduced, the percentage of people screened for HCV rose from 34% to 46%, the number of patients starting treatment increased by 11%, and the number of people cured jumped by 37%. This matters because it shows that better coordination and tracking in healthcare can lead to more effective treatment and fewer cases of this serious disease. Who this helps: This helps patients with hepatitis C by improving their chances of timely diagnosis and successful treatment.

Plain English
This study focused on creating models of breast cancer derived from actual patients to better understand hormone receptor-positive, HER2-negative cancers, especially those resistant to hormone therapy. Researchers successfully developed seven patient-derived models from 28 tumors, with a notable finding that the average time to grow these models was about 100 days for hormone-resistant tumors and 178 days for untreated tumors. These models accurately reflected the characteristics of the original patient tumors, providing valuable insights for developing new treatments. Who this helps: Patients with hormone-resistant breast cancer and their doctors.

Plain English
This study looked at the effects of a type of medication called glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for treating obesity and type 2 diabetes. Researchers found that using these medications may lead to problems with the muscles in the esophagus, which helps move food down to the stomach. Specifically, 12% of adults in the U.S. have used GLP-1RAs, highlighting the need for awareness of potential side effects on swallowing and digestive function. Who this helps: This information helps patients taking GLP-1RAs and their doctors.

Plain English
Researchers studied whether esophageal high-resolution manometry (HRM), a test for checking how well the esophagus works, can be safely performed on patients using a type of medication called GLP-1 receptor agonists (GLP-1RAs), commonly used for weight loss and diabetes. They found that out of 166 patients, only 15 (9%) could not complete the test due to discomfort, with no significant difference between those on GLP-1RAs and those who were not (10.8% vs. 7.2%). This study shows that using GLP-1RAs does not increase the risk of problems during HRM, meaning patients can safely undergo this important diagnostic test even if they are on these medications. Who this helps: Patients taking GLP-1RAs for obesity or diabetes who need esophageal testing.

Plain English
This study looked at the weight loss results of patients taking semaglutide, a medication for obesity, and compared those who had never taken anti-obesity medications (AOM-naïve) with those who had previously used them (non-AOM-naïve). The findings showed that after 12 months, those who were AOM-naïve lost an average of 14.3% of their body weight, while the non-AOM-naïve group only lost 10.6%. This research matters because it highlights that patients new to anti-obesity medications may respond better to semaglutide than those with prior medication experience. Who this helps: This helps patients struggling with obesity, particularly those who have not tried other weight loss medications before.

Plain English
This study looked at how different weight loss surgeries affect gut movements and hormones in patients with obesity. It found that Roux-en-Y gastric bypass (RYGB) and laparoscopic sleeve gastrectomy (LSG) decrease a hormone called leptin and increase others like GLP-1 and PYY, which help control appetite. Additionally, RYGB and LSG speed up how quickly the stomach empties food, while endoscopic sleeve gastroplasty (ESG) slows down gastric movements but still lowers leptin and raises GLP-1 and ghrelin. Who this helps: This research benefits patients undergoing weight loss surgeries and healthcare providers involved in obesity treatment.

Plain English
This study looked at the results of a safe procedure called bedside ultrasound-guided percutaneous cholecystostomy (PC) for critically ill patients in the ICU. Out of 51 patients, the procedure was technically successful for everyone, with a clinical improvement in 92% of cases; 86% later had surgery to remove their gallbladder. This matters because it provides a reliable option for patients who cannot undergo immediate surgery due to their condition, improving their chances of recovery. Who this helps: This helps critically ill patients who suffer from gallbladder issues and their doctors.

Plain English
This research studied how well the individualized metabolic score (IMS) can predict whether people with obesity and type 2 diabetes will see their diabetes go into remission after a specific weight-loss procedure called endoscopic sleeve gastroplasty (ESG). They found that 60% of patients with a mild IMS score achieved diabetes remission, compared to 45.5% with a moderate score and none with a severe score. This information is important because it helps identify which patients are more likely to benefit from ESG based on their IMS score. Who this helps: This helps patients with obesity and type 2 diabetes considering endoscopic sleeve gastroplasty.

Plain English
This study examined the use of a treatment called peptide receptor radionuclide therapy (PRRT) with Lu-177 DOTATATE for patients with aggressive meningiomas that did not respond to other therapies. Out of eight patients treated, the average time before the cancer worsened was about 8.9 months, and while one patient’s cancer progressed, seven others had stable disease after treatment. This finding is important because it shows that PRRT is a safe and effective option for difficult-to-treat meningiomas, especially when given via an intra-arterial approach, which delivers a higher dose of the drug. Who this helps: This helps patients with advanced meningiomas who have limited treatment options.

Plain English
This study looked at a treatment method called metronomic therapy for patients with desmoid fibromatosis, a type of tumor that isn’t usually fatal but affects patients’ quality of life. The researchers treated 315 patients over a median follow-up period of 36 months and found that 81.1% were still free from tumor growth after three years, and 99.2% were still alive. This therapy is affordable at about $130 a year and has fewer side effects compared to other treatments, making it an important option for patients needing care. Who this helps: This benefits patients with desmoid fibromatosis and their healthcare providers.

Plain English
This study looked at how the severity of type 2 diabetes affects weight loss in patients taking a medication called semaglutide. Researchers found that over 12 months, patients with mild to moderate diabetes lost an average of 8.3% of their body weight, while those with severe diabetes lost only 5.5%. Understanding this relationship matters because it can help tailor treatments for weight loss in patients with different levels of diabetes severity. Who this helps: This helps patients with obesity and type 2 diabetes.

Plain English
This study looked at how well ChatGPT, an AI chatbot, answers questions about Endoscopic Sleeve Gastroplasty (ESG) compared to information from hospital websites, based on evaluations from 12 medical professionals with ESG expertise. They found that while ChatGPT's average rating was 2.75 out of 5, it actually provided a more accurate definition of ESG than traditional sources (4.33 vs. 3.61). This shows that ChatGPT can be a reliable source of information for patients considering ESG and can match the quality of standard medical resources. Who this helps: Patients seeking information about Endoscopic Sleeve Gastroplasty.

Plain English
This study looked at how a liver test called the ICG-R15 can predict the risk of liver failure after major liver surgery in patients with liver cancer. They examined 72 patients and found that 39% experienced liver failure after the surgery, with varying severity levels. The findings show that using the ICG-R15 test can help identify patients at higher risk, allowing for better planning and safer surgeries. Who this helps: This helps patients undergoing liver surgery and their doctors in making informed decisions.

Plain English
This study looked at a treatment called hepatic artery infusion chemotherapy (HAIC) for patients with colorectal cancer that has spread to the liver. Out of 12 patients treated, 9 (or 64%) were free of disease after completing the therapy, which involved an average of four sessions, and none had immediate side effects. This finding is important because it shows that HAIC can be safely and effectively used in this setting, offering a viable option for high-risk patients with liver metastasis. Who this helps: This benefits patients with colorectal liver metastasis and their doctors by providing a new treatment option.

Plain English
This study looked at how taking weight loss medications alongside a procedure called endoscopic sleeve gastroplasty (ESG) affects weight loss in patients. It included 1,506 patients and found that those who were using weight loss medications during the procedure had less weight loss after 6 months compared to those who weren’t using them. However, patients who started using these medications after the first year saw better results after 24 months. This matters because it shows that the timing of weight loss medication can significantly influence the effectiveness of the ESG procedure. Who this helps: This helps patients seeking effective weight loss strategies after undergoing ESG.

Plain English
This study looked at the diversity of participants in clinical trials for bariatric surgery, analyzing data from 117 trials with over 8,400 participants. Researchers found that most participants were aged between 18 and 65, predominantly female (74.9%), and mostly White (65.3%), with very few individuals from racial minority groups like African Americans (18.5%) and Hispanics (17.6%). These findings highlight serious gaps in representation, which could affect the effectiveness and fairness of weight loss treatments for all groups. Who this helps: This information benefits patients and healthcare providers by promoting better, more equitable care for everyone considering bariatric surgery.

Plain English
This study looked at how a procedure called transarterial embolization (TAE) affects the presence of circulating tumor cells (CTCs) in patients with large liver tumors before and after surgery. Researchers found that out of 10 patients, 4 had CTCs both before and 30 days after surgery, while 2 had CTCs before but cleared them by the 30-day mark, leading to better survival for those patients. This matters because clearing CTCs could be an important indicator of survival in liver cancer patients, suggesting a need for more research in this area. Who this helps: This benefits patients with liver cancer and their doctors.

Plain English
This study looked at a treatment called intra-arterial PRRT using a substance called Lu-177 DOTATATE for patients with liver-focused metastatic neuroendocrine tumors. Out of 14 patients, 9 showed a partial response to the treatment, while 5 had stable disease. The treatment was found to be safe, with few side effects, such as some patients experiencing temporary changes in liver or kidney function that returned to normal. Who this helps: This helps patients with liver-dominant metastatic neuroendocrine tumors.

Plain English
This study looked at the impact of bile leaks that can occur after liver surgery in patients with different types of liver tumors. Researchers analyzed data from 862 patients and found that those with cholangiocarcinoma who experienced bile leaks had a shorter disease-free survival time of about 9.9 months compared to 24.9 months for those without leaks. This is important because it highlights the need for better prevention and treatment strategies for bile leaks, particularly in patients with cholangiocarcinoma, to improve their long-term outcomes. Who this helps: This helps patients with cholangiocarcinoma and their doctors.

Plain English
This study looked at how often patients achieved a "textbook outcome" after liver surgery for tumors, which is a standard way to measure the quality of surgical results. Out of 1,018 patients, 64.9% experienced this ideal outcome, with the main factor preventing it being serious liver failure after surgery, which affected 22% of patients. Achieving this ideal outcome was linked to better chances of surviving both overall and without disease, highlighting the importance of the findings for improving patient care. Who this helps: This benefits patients undergoing liver surgery and their doctors by providing a tool to predict recovery success.

Plain English
This study examined the imaging characteristics of chondroblastoma, a type of bone tumor, using data from 52 patients treated between 2010 and 2022. Researchers found that most patients (75%) were young, with an average age of 18 years, and the tumors were typically located in the long bones of the arms and legs. Notably, all the tumors showed unique imaging features that help differentiate them from other similar benign tumors, and none of the patients developed metastasis during the follow-up period, which lasted around 71 months. Who this helps: This research benefits doctors by providing clearer imaging criteria for diagnosing chondroblastoma.

Plain English
This study looks at advanced tools for stitching tissue inside the body using a technique called endoscopy, which has applications in weight loss surgeries and other medical procedures. The researchers note that currently, the only widely available device in the U.S. is the OverStitch system, but they also discuss several new devices being developed or tested for weight loss, like the USGI incisionless operating platform and Endomina. These advancements are important because they may make weight loss surgeries safer and more effective for patients. Who this helps: This helps patients seeking weight loss solutions through less invasive surgical options.

Plain English
This study focused on how precision medicine can improve treatment for obesity through bariatric procedures. By considering personal traits like genetics and behavior, researchers found that customized approaches to treatment can lead to better outcomes for patients. For instance, providing tailored interventions may result in a higher success rate for weight loss compared to one-size-fits-all methods. Who this helps: This benefits patients struggling with obesity.

Plain English
This paper corrects previous findings about using weight-loss drugs alongside a procedure called endoscopic sleeve gastroplasty, which is used to help people lose weight. The study looked at patient outcomes and found that those using antiobesity medications had better results in losing weight compared to those who did not. This is important because it highlights a combination approach to treatment that could lead to more effective weight loss for patients. Who this helps: Patients who are struggling with obesity and seeking effective treatment options.

Plain English
This study looked at how specific genetic changes in the leptin-melanocortin pathway affect weight loss in obese patients who had weight loss surgery and then underwent a follow-up procedure called endoscopic transoral outlet reduction (TORe). Researchers found that patients with these genetic changes lost significantly less weight at 12 months—averaging 0.68% compared to 9.6% for those without the variants—indicating that these genetic differences impact the success of the follow-up procedure. This information is important because it helps identify which patients might struggle with weight loss after surgery, leading to better personalized treatment plans. Who this helps: This helps doctors and their patients in managing obesity treatment more effectively.

Plain English
This study looked at the effects of using basiliximab, a medication to help prevent rejection, in heart transplant patients from 2003 to 2020. It found that while basiliximab reduced the chance of acute cellular rejection (ACR) from 50% to 36%, it increased the risk of antibody-mediated rejection (AMR) to 9.7% compared to none in the group without basiliximab. Both groups had similar rates of infections and cancer, but those who received basiliximab had a higher risk of death after the transplant. Who this helps: This helps heart transplant patients and their doctors in making informed decisions about post-transplant care.